vs

Side-by-side financial comparison of INNODATA INC (INOD) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

INNODATA INC is the larger business by last-quarter revenue ($72.4M vs $69.8M, roughly 1.0× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 12.2%, a 371.8% gap on every dollar of revenue. On growth, INNODATA INC posted the faster year-over-year revenue change (22.3% vs 21.2%). Over the past eight quarters, INNODATA INC's revenue compounded faster (65.3% CAGR vs 53.7%).

Innodata Inc., formerly Innodata Isogen, Inc., is an American company that provides business process, technology and consulting services. The company also provides products that aim to help clients create, manage, use and distribute digital information.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

INOD vs RIGL — Head-to-Head

Bigger by revenue
INOD
INOD
1.0× larger
INOD
$72.4M
$69.8M
RIGL
Growing faster (revenue YoY)
INOD
INOD
+1.1% gap
INOD
22.3%
21.2%
RIGL
Higher net margin
RIGL
RIGL
371.8% more per $
RIGL
384.0%
12.2%
INOD
Faster 2-yr revenue CAGR
INOD
INOD
Annualised
INOD
65.3%
53.7%
RIGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INOD
INOD
RIGL
RIGL
Revenue
$72.4M
$69.8M
Net Profit
$8.8M
$268.1M
Gross Margin
38.3%
91.5%
Operating Margin
15.1%
33.2%
Net Margin
12.2%
384.0%
Revenue YoY
22.3%
21.2%
Net Profit YoY
-14.2%
1769.2%
EPS (diluted)
$0.26
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INOD
INOD
RIGL
RIGL
Q4 25
$72.4M
$69.8M
Q3 25
$62.5M
$69.5M
Q2 25
$58.4M
$101.7M
Q1 25
$58.3M
$53.3M
Q4 24
$59.2M
$57.6M
Q3 24
$52.2M
$55.3M
Q2 24
$32.6M
$36.8M
Q1 24
$26.5M
$29.5M
Net Profit
INOD
INOD
RIGL
RIGL
Q4 25
$8.8M
$268.1M
Q3 25
$8.3M
$27.9M
Q2 25
$7.2M
$59.6M
Q1 25
$7.8M
$11.4M
Q4 24
$10.3M
$14.3M
Q3 24
$17.4M
$12.4M
Q2 24
$-14.0K
$-1.0M
Q1 24
$989.0K
$-8.2M
Gross Margin
INOD
INOD
RIGL
RIGL
Q4 25
38.3%
91.5%
Q3 25
40.8%
93.2%
Q2 25
39.4%
95.6%
Q1 25
39.9%
91.7%
Q4 24
45.2%
89.9%
Q3 24
40.8%
85.5%
Q2 24
28.7%
92.4%
Q1 24
36.4%
93.1%
Operating Margin
INOD
INOD
RIGL
RIGL
Q4 25
15.1%
33.2%
Q3 25
18.8%
40.9%
Q2 25
15.3%
60.1%
Q1 25
14.2%
23.9%
Q4 24
19.0%
28.9%
Q3 24
21.9%
25.4%
Q2 24
1.0%
1.2%
Q1 24
5.0%
-23.6%
Net Margin
INOD
INOD
RIGL
RIGL
Q4 25
12.2%
384.0%
Q3 25
13.3%
40.2%
Q2 25
12.4%
58.6%
Q1 25
13.3%
21.5%
Q4 24
17.4%
24.9%
Q3 24
33.3%
22.5%
Q2 24
-0.0%
-2.8%
Q1 24
3.7%
-27.9%
EPS (diluted)
INOD
INOD
RIGL
RIGL
Q4 25
$0.26
$14.11
Q3 25
$0.24
$1.46
Q2 25
$0.20
$3.28
Q1 25
$0.22
$0.63
Q4 24
$0.35
$0.82
Q3 24
$0.51
$0.70
Q2 24
$0.00
$-0.06
Q1 24
$0.03
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INOD
INOD
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$82.2M
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$107.1M
$391.5M
Total Assets
$168.6M
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INOD
INOD
RIGL
RIGL
Q4 25
$82.2M
$155.0M
Q3 25
$73.9M
$137.1M
Q2 25
$59.8M
$108.4M
Q1 25
$56.6M
$77.1M
Q4 24
$46.9M
$77.3M
Q3 24
$26.4M
$61.1M
Q2 24
$16.5M
$49.1M
Q1 24
$19.0M
$49.5M
Total Debt
INOD
INOD
RIGL
RIGL
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
INOD
INOD
RIGL
RIGL
Q4 25
$107.1M
$391.5M
Q3 25
$97.3M
$117.6M
Q2 25
$86.7M
$81.9M
Q1 25
$75.5M
$18.6M
Q4 24
$63.5M
$3.3M
Q3 24
$47.7M
$-14.6M
Q2 24
$29.0M
$-29.9M
Q1 24
$27.6M
$-31.7M
Total Assets
INOD
INOD
RIGL
RIGL
Q4 25
$168.6M
$513.6M
Q3 25
$152.9M
$242.5M
Q2 25
$132.6M
$206.7M
Q1 25
$125.2M
$176.0M
Q4 24
$113.4M
$164.0M
Q3 24
$88.2M
$139.4M
Q2 24
$66.0M
$128.4M
Q1 24
$63.6M
$126.5M
Debt / Equity
INOD
INOD
RIGL
RIGL
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INOD
INOD
RIGL
RIGL
Operating Cash FlowLast quarter
$12.9M
$22.0M
Free Cash FlowOCF − Capex
$10.1M
FCF MarginFCF / Revenue
13.9%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
1.46×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$35.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INOD
INOD
RIGL
RIGL
Q4 25
$12.9M
$22.0M
Q3 25
$18.8M
$24.0M
Q2 25
$4.2M
$30.5M
Q1 25
$10.9M
$-893.0K
Q4 24
$17.2M
$14.5M
Q3 24
$11.4M
$21.7M
Q2 24
$-454.0K
$302.0K
Q1 24
$6.8M
$-5.0M
Free Cash Flow
INOD
INOD
RIGL
RIGL
Q4 25
$10.1M
Q3 25
$14.5M
Q2 25
$2.5M
Q1 25
$8.5M
Q4 24
$15.0M
Q3 24
$9.9M
Q2 24
$-3.2M
Q1 24
$5.4M
FCF Margin
INOD
INOD
RIGL
RIGL
Q4 25
13.9%
Q3 25
23.2%
Q2 25
4.3%
Q1 25
14.6%
Q4 24
25.3%
Q3 24
19.0%
Q2 24
-9.8%
Q1 24
20.5%
Capex Intensity
INOD
INOD
RIGL
RIGL
Q4 25
3.9%
Q3 25
6.8%
Q2 25
2.9%
Q1 25
4.0%
Q4 24
3.7%
Q3 24
2.8%
Q2 24
8.4%
Q1 24
5.1%
Cash Conversion
INOD
INOD
RIGL
RIGL
Q4 25
1.46×
0.08×
Q3 25
2.25×
0.86×
Q2 25
0.59×
0.51×
Q1 25
1.40×
-0.08×
Q4 24
1.67×
1.01×
Q3 24
0.65×
1.75×
Q2 24
Q1 24
6.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons